Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapyNicola Gaynor(Dublin City University), Denis M. Collins(Dublin City University)British Journal of CancerJuly 28, 202310.1038/s41416-023-02375-yCited by 12SaveCiteExport RISWatch citationsRelated PapersEffects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer|Clinical Cancer Research|2020|75Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer|PLoS ONE|2017|54